Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
Peter Hoskin(Northwood University), Oliver Sartor, Joe M. O’Sullivan(Queen's University Belfast), Dag Clement Johannessen(Oslo University Hospital), Svein Inge Helle(Haukeland University Hospital), John Logue(The Christie Hospital), David Bottomley(St James's University Hospital), Sten Nilsson(Karolinska University Hospital), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Fang Fang(Bayer (United States)), Mona Wahba(Bayer (United States)), Anne-Kirsti Aksnes(Bayer (Norway)), Christopher Parker(Institute of Cancer Research)
Cited by 406
Abstract
Related Papers
No related papers found
Powered by citation graph analysis